AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

AIM expects the patient-program findings and upcoming DURIPANC data to help inform the design of a planned pivotal trial.

Rhea-AI Summary

AIM ImmunoTech (AIM) highlighted Ampligen’s pancreatic cancer development strategy as the Phase 2 DURIPANC trial completed final Ampligen dosing.

DURIPANC evaluates Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. AIM expects topline results in the first quarter of 2027. Interim reports suggest activation of both innate and adaptive immune responses; the combination was reported as well-tolerated, with patients reporting high quality of life throughout treatment.

AIM also completed a Netherlands-approved Named Patient Program involving 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX, who received Ampligen as maintenance treatment. The company described survival, safety and quality-of-life findings as encouraging.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointDURIPANC completed final Ampligen dosing, advancing the Phase 2 program toward topline results.
• Moderate point. Forward-looking: it has not happened yet and may not happen.AIM expects DURIPANC topline results in the first quarter of 2027.
• Moderate point. Forward-looking: it has not happened yet and may not happen.AIM plans a pivotal clinical trial, with its design informed by patient-program and upcoming DURIPANC data.
• Minor pointInterim DURIPANC reports suggest innate and adaptive immune activation with Ampligen plus Imfinzi.
• Minor pointDURIPANC combination treatment was reported as well-tolerated, with patients consistently reporting high quality of life.
• Minor pointCompleted 57-patient Named Patient Program produced survival, safety and quality-of-life findings AIM described as encouraging.

Negative

• None.

News Explained

AIM says exploratory biomarker analyses with DURIPANC results expected in the first quarter of 2027 may help it understand patient response and inform the design of a planned pivotal trial; the release does not specify that trial’s design.

Key Figures

Named Patient Program patients: 57 patients DURIPANC trial phase: Phase 2 Topline results timing: First quarter of 2027

Named Patient Program patients

57 patients

Ampligen maintenance treatment after FOLFIRINOX

DURIPANC trial phase

Phase 2

Ampligen in combination with Imfinzi for metastatic pancreatic cancer

Topline results timing

First quarter of 2027

DURIPANC

Previous Clinical trial Reports

3 past events · Latest: Jun 18

Same Type 3 events

1. Jun 18

   Trial dosing milestone

   24h Move

   -5.0%

   Final subject received first dose of Ampligen plus Imfinzi in Phase 2 DURIPANC.

2. Jun 08

   Interim trial progress

   24h Move

   +0.6%

   Reported positive mid-year interim progress and final patient enrollment in DURIPANC.

3. Jun 01

   Enrollment milestone

   24h Move

   +120.3%

   Completed enrollment more than one month ahead of target; final dosing was planned for mid-June.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

named patient program, folfirinox, checkpoint inhibition, innate and adaptive responses

4 terms

named patient program medical

"Netherlands-approved Named Patient Program (“NPP”)"

A named patient program lets a specific individual receive a drug or treatment that is not yet approved or not available in their country, with a doctor arranging access outside the usual approval channels. For investors, these programs can provide early, small-scale sales, real-world use data and signals about demand or safety, but they are unpredictable and not a substitute for broad market approval—think of it as a limited test-drive before full product launch.

folfirinox medical

"after FOLFIRINOX received Ampligen as a maintenance treatment"

FOLFIRINOX is a combination chemotherapy treatment made up of several anti-cancer drugs given together to treat advanced cancers, most often pancreatic cancer. Investors watch it because its effectiveness, side effects and approval or use guidelines influence sales of the component drugs, demand for alternative therapies, hospital treatment patterns and the financial prospects of companies running clinical trials or selling supportive care for these patients—think of it as a widely used multi-drug toolkit whose performance shapes related markets.

checkpoint inhibition medical

"the rationale for evaluating the drug in combination with checkpoint inhibition"

Checkpoint inhibition is a type of cancer treatment that blocks certain proteins on immune cells or tumors that act like brakes, allowing the body’s T cells to attack cancer more strongly. For investors, it matters because these therapies can transform clinical trial outcomes, drive regulatory approvals or safety concerns, and create large market opportunities or partnership and pricing questions—similar to taking the foot off a brake to speed up a car but increasing the risk of losing control.

innate and adaptive responses medical

"coordinated activation of innate and adaptive responses"

The innate and adaptive responses are the two main parts of the immune system. The innate response acts first and provides general, immediate defense against pathogens using barriers (like skin), cells that attack anything foreign (like neutrophils and macrophages), and inflammatory signals; the adaptive response develops more slowly and targets specific threats using specialized lymphocytes (B cells that make antibodies and T cells that kill infected cells or help other immune cells). The innate response gives quick, broad protection and helps trigger and shape the adaptive response, while the adaptive response provides tailored, stronger defense and immunological memory for faster action on repeat exposures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program

OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resistance and the continued advancement of the Phase 2 DURIPANC clinical trial (“DURIPANC”).

Recent coverage includes:

• Med World News: AIM ImmunoTech’s Ampligen Program Targets One of Pancreatic Cancer’s Hardest Barriers
• Pharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting Immune Resistance in Pancreatic Cancer

Pancreatic cancer remains one of the most difficult cancers to treat, in part because of an immunosuppressive tumor microenvironment that can limit the effectiveness of immune-based therapies. Recent features have examined Ampligen’s potential to help address this challenge through its immune-modulating activity and the rationale for evaluating the drug in combination with checkpoint inhibition.

AIM successfully concluded a Netherlands-approved Named Patient Program (“NPP”) in which 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment, with highly encouraging findings of Overall Survival, safety and improved Quality of Life. Ampligen is also being evaluated in combination with AstraZeneca’s Imfinzi® (durvalumab) in the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, with interim reports of immune system changes that suggest a coordinated activation of innate and adaptive responses, and all while the combination therapy is reported as being well-tolerated and patients consistently report a high Quality of Life throughout treatment. The study has completed final Ampligen dosing, representing an important clinical milestone as the program advances toward topline results expected in the first quarter of 2027.

“The recent media attention around Ampligen reflects the important scientific rationale behind our pancreatic cancer strategy, supported by the meaningful clinical progress we have made with DURIPANC,” said AIM Chief Executive Officer Thomas K. Equels. “With DURIPANC final Ampligen dosing complete and topline results expected in the first quarter of 2027, we are approaching an important inflection point for the program. We believe that the NPP data combined with the upcoming DURIPANC data – including exploratory biomarker analyses that may help AIM to better understand patient response – will provide important insight into Ampligen’s potential role in metastatic pancreatic cancer and help inform the design of a planned pivotal clinical trial.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address immune resistance in pancreatic cancer through its immune-modulating activity; the potential of Ampligen in combination with AstraZeneca’s Imfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing and outcome of the DURIPANC topline results; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does AIM expect DURIPANC pancreatic cancer trial results?

AIM expects DURIPANC topline results in the first quarter of 2027. The Phase 2 trial has completed final Ampligen dosing and evaluates Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.

How will AIM use DURIPANC biomarker analyses?

AIM believes exploratory biomarker analyses may help it better understand patient response. The company expects the upcoming DURIPANC data, together with Named Patient Program findings, to help inform the design of a planned pivotal clinical trial.